Merck & Co. Inc. made a big announcement over its osteoporosis pipeline drug, odanacatib. The company is discontinuing the development of the drug, citing that the overall benefit-risk profile does not support filing or further development. Odanacatib or MK-0822, which was being developed as a once-weekly oral treatment of osteoporosis in post-menopausal women, showed an … Continue reading “Merck & Co.(MRK) Just Discontinued This Major Pipeline Drug”
